目的 观察保妇康栓联合头孢曲松钠、甲硝唑治疗慢性盆腔炎的临床疗效。方法 选取2013年6月—2014年6月西安市第九医院收治的慢性盆腔炎患者80例, 随机分为对照组和治疗组, 每组40例。对照组患者给予注射用头孢曲松钠2.0 g加入生理盐水250 mL, 静脉滴注, 1次/d;同时静脉滴注甲硝唑葡萄糖注射液250 mL, 1次/d。治疗组在对照组基础上, 月经结束后3 d开始睡前使用保妇康栓, 1次/d。两组均连续治疗21 d。观察两组的临床疗效, 同时比较两组临床症状改善情况、炎症因子检测水平、超声检查情况及复发率。结果 治疗后, 对照组和治疗组的总有效率分别为72.5%、92.5%, 两组总有效率比较差异有统计学意义(P<0.05)。治疗后, 两组患者的临床症状及影像学检查均较治疗前明显好转, 且治疗组优于对照组(P<0.05)。两组患者TNF-α、IL-8、TGF-β1、IL-1β均较同组治疗前显著降低, 同组治疗前后差异有统计学意义(P<0.05);且治疗组这些观察指标的改善程度优于对照组, 两组比较差异有统计学意义(P<0.05)。对照组和治疗组的复发率分别为17.5%、2.7%, 两组复发率比较差异有统计学意义(P<0.05)。结论 保妇康栓联合头孢曲松钠、甲硝唑治疗慢性盆腔炎具有较好的临床疗效, 可减轻患者的临床症状, 降低炎症因子水平, 在临床具有一定的推广应用价值。

Objective To explore the efficacy of Baofukang Suppository combined with ceftriaxone sodium and metronidazole in treatment of chronic pelvic inflammatory. Methods Patients (80 cases) with chronic pelvic inflammatory in Ninth Hospital of Xi'an from June 2013 to June 2014 were randomly divided into control and treatment groups, and each group had 40 cases. The patients in the control group were iv administered with Ceftriaxone Sodium for injection 2.0 g adding into physiological saline 250 mL, once daily. At the same time, they were iv administered with Metronidazole and Glucose Injection 250 mL, once daily. The patients in the treatment group were given Baofukang Suppository before going to sleep 3 d after menstruation on the basis of the control group, once daily. Two groups were treated for 21 d. After treatment, the efficacy was evaluated, and improvement situation of clinical symptoms, levels of inflammatory factors, ultrasound situation and recurrence rate in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 72.5% and 92.5%, respectively, and there were differences between two groups (P < 0.05). The clinical symptoms and imaging examination in two groups were improved markedly, and these situations in the treatment group were better than those in the control group (P < 0.05). TNF-α, IL-8, TGF-β1, and IL-1β in two groups were significantly reduced, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment group improved better than those in the control group, with significant differences between two groups (P < 0.05). The recurrence rate in the control and treatment groups were 17.5% and 2.7%, respectively, and there were differences between two groups (P < 0.05). Conclusion Baofukang Suppository combined with ceftriaxone sodium and metronidazole has good clinical efficacy in treatment of chronic pelvic inflammatory, and can reduce the clinical symptoms, while can lower inflammatory cytokines levels, which has certain application value in clinical.